Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3203453 | 0.84 | ALDH1A1 (0.72) | ALDH1A1HTTLMNASMN1; SMN2MEN1 | |
| SCHEMBL3216795 | 0.84 | ATM (0.70) | ALDH1A1HTTLMNASMN1; SMN2KDM4E | |
| SCHEMBL1353693 | 0.82 | ALDH1A1 (0.72) | ALDH1A1HTTLMNASMN1; SMN2KDM4E | |
| SCHEMBL25522803 | 0.82 | ALDH1A1 (0.72) | ALDH1A1HTTLMNASMN1; SMN2KDM4E | |
| SCHEMBL17896865 | 0.82 | ALDH1A1 (0.82) | ALDH1A1HTTLMNASMN1; SMN2 | |
| SCHEMBL10122851 | 0.81 | LMNA (1.00) | ALDH1A1HTTLMNASMN1; SMN2KDM4E | |
| SCHEMBL3230823 | 0.80 | HTR7 (0.63) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL19016264 | 0.79 | ALDH1A1 (0.67) | ALDH1A1HTTLMNASMN1; SMN2MEN1 | |
| SCHEMBL29362316 | 0.79 | POLB (0.77) | ALDH1A1HTTLMNASMN1; SMN2KDM4E | |
| SCHEMBL17896350 | 0.79 | ALDH1A1 (0.67) | ALDH1A1HTTLMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | claimed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006022955-A2 | TOPOISOMERASE INHIBITORS | PROPHARMACON, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | ALDH1A1 3255/4885HTT 2211/4885LMNA 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.